Nivolumab (new indication: gastric, gastro-esophageal junction (GEJ) or esophageal adenocarcinoma, CPS ≥ 5 HER2-, first-line therapy in combination with fluoropyrimidine-and platinum-based combination chemotherapy)

Subject:

• Active Substance: Nivolumab
• Name: Opdivo^®
• Therapeutic area: Gastric, gastro-esophageal junction (GEJ) or esophageal adenocarcinoma
• Pharmaceutical company: Bristol-Myers Squibb GmbH & Co. KGaA

Time table:

• Start: 01.12.2021
• Final decision by G-BA: 19.05.2022

Final decision:

• Hint for a considerable additional benefit